Regeneron Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals

REGN 784.45

-0.4%

Nov 26 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Biotech Jim	2/20/2015 10:07:24 AM
	of 3559

Olivier Brandicourt, the new CEO at SNY, should be very good for the collaboration. At PFE he was major league involved n the Lipitor franchise, and at Bayer-Europe he got to know first hand the REGN collaboration with Eylea. Can Brandicourt influence and lead in the PCSK9 PBM battles and AMGN/PFE/others turf wars that lie ahead? He perhaps has the best knowledge base, considering this highly relevant history. (I would love to be a fly on the wall to listen to PCSK9 discussions between Vagelos, Yancopoulos, and Brandicourt - talk about experts.) If he can, I will invite all to toast a fine brandy at my place. I think REGN will ultimately make it big in oncology, but that is further in the future. Before that we have metabolic/lipids, inflammation and allergy/asthma, Should be an educational run at least. Congrats to the long term researchers at REGN, and good luck to all the patients. (Did I use enuf acronyms in this post?)

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next